Barchart on MSN2h
This Little-Known Stock Just Doubled on Weight-Loss Drug News. Analysts Think It Has 400% Upside Potential From Here.
Growing demand for weight-loss solutions has catapulted pharmaceutical firms like Eli Lilly (LLY) and Novo Nordisk (NVO) into ...
Hosted on MSN13h
Novo Nordisk shares surge on results of new obesity drug trial
Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...
IPWatchdog4h
The Growing Market for Weight Loss Treatments: Innovation, Patents, and the Future of GLP-1 Agonists
In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...
Novo Nordisk's Ozempic gets FDA approval for kidney disease
Novo Nordisk (NVO) said its popular diabetes drug Ozempic, or semaglutide, has been approved for the treatment of patients ...
MM&M6h
Hims & Hers set for Super Bowl ad debut highlighting GLP-1 weight loss drugs
Hims & Hers’ decision to advertise at the Super Bowl represents an ambitious play for the brand as it positions itself in the ...
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding use in U.S.
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
pharmaphorum23h
Lilly gets FDA OK for Alzheimer’s drug, cites cost advantage
Eli Lilly finally has FDA approval for its ... Some analysts have suggested that Lilly’s drug may have a greater tendency to cause serious side effects known as ARIA, which are rare for both ...
pharmaphorum23h
FDA’s treatment of China-developed drugs spurs demands for multiregional clinical trials
China’s emergence as an R&D powerhouse means that the country is quickly adding a number of drug candidates to the ... after previously moving against Eli Lilly and Innovent Biologics ...